Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications.

Autor: Adly AAM; Pediatric Department, Faculty of Medicine, Ain Shams University, Egypt. Electronic address: amiradiabetes@yahoo.com., Ismail EA; Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt., Tawfik LM; Clinical Pathology Department, Faculty of Medicine, Ain Shams University, Egypt., Ebeid FSE; Pediatric Department, Faculty of Medicine, Ain Shams University, Egypt., Hassan AAS; Pediatric Department, Faculty of Medicine, Ain Shams University, Egypt.
Jazyk: angličtina
Zdroj: Cytokine [Cytokine] 2015 Dec; Vol. 76 (2), pp. 156-162. Date of Electronic Publication: 2015 Jul 02.
DOI: 10.1016/j.cyto.2015.06.006
Abstrakt: Objectives: Endothelial monocyte-activating polypeptide II (EMAP II) is a multifunctional polypeptide with proinflammatory and antiangiogenic activity. Hyperglycemia and dyslipidemia appears to be significant factors contributing to increased EMAP-II levels. We determined serum EMAP II in children and adolescents with type 1 diabetes as a potential marker for micro-vascular complications and assessed its relation to inflammation and glycemic control.
Methods: Eighty children and adolescents with type 1 diabetes were divided into 2 groups according to the presence of micro-vascular complications and compared with 40 healthy controls. High-sensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c) and EMAP II levels were assessed.
Results: Serum EMAP II levels were significantly increased in patients with micro-vascular complications (1539 ± 321.5 pg/mL) and those without complications (843.6 ± 212.6 pg/mL) compared with healthy controls (153.3 ± 28.3 pg/mL; p<0.001). EMAP II was increased in patients with microalbuminuria than normoalbuminuric group (p<0.001). Significant positive correlations were found between EMAP II levels and body mass index, fasting blood glucose, HbA1c, serum creatinine, triglycerides, total cholesterol, urinary albumin creatinine ratio (UACR) and hs-CRP (p<0.05). A cutoff value of EMAP II at 1075 pg/mL could differentiate diabetic patients with and without micro-vascular complications with a sensitivity of 93% and specificity of 82%.
Conclusions: We suggest that EMAP II is elevated in type 1 diabetic patients, particularly those with micro-vascular complications. EMAP II levels are related to inflammation, glycemic control, albuminuria level of patients and the risk of micro-vascular complications.
(Copyright © 2015 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: